AstraZeneca PLC (LON:AZN)’s share price dropped 0.5% on Monday . The company traded as low as GBX 4,734.50 ($63.72) and last traded at GBX 4,745 ($63.86). Approximately 1,823,066 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 2,180,000 shares. The stock had previously closed at GBX 4,767 ($64.16).

A number of brokerages have commented on AZN. Liberum Capital restated a “buy” rating and set a GBX 4,800 ($64.60) price objective on shares of AstraZeneca in a research report on Tuesday, September 5th. raised their price objective on AstraZeneca from GBX 4,100 ($55.18) to GBX 4,150 ($55.85) and gave the stock a “reduce” rating in a research report on Monday, October 9th. UBS set a GBX 4,550 ($61.24) price objective on AstraZeneca and gave the stock a “neutral” rating in a research report on Monday, October 23rd. Jefferies Group raised their price objective on AstraZeneca from GBX 4,350 ($58.55) to GBX 4,800 ($64.60) and gave the stock a “hold” rating in a research report on Monday, September 11th. Finally, Deutsche Bank restated a “buy” rating and set a GBX 5,600 ($75.37) price objective on shares of AstraZeneca in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of GBX 5,169 ($69.57).

TRADEMARK VIOLATION NOTICE: “AstraZeneca (AZN) Shares Down 0.5%” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/06/astrazeneca-azn-shares-down-0-5.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Stock Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related stocks with our FREE daily email newsletter.